Novartis AG (NOVN)
Healthcare • Drug Manufacturers - General
StockSwissSwitzerlandCH0012005267
134.16 CHF
-0.04% today Updated 13 Nov 2026 13:10
Kyvero is an independent information site. It is not affiliated with, endorsed by or sponsored by Novartis AG, and has no access to any account you may have with it. The name and the logo belong to their owners.
Price history
Daily prices in CHF. Dividends, results and news are marked on the day they happened; click a day to see them.
Updated 13 Nov 2026 13:10. Information, not advice. Showing the last 12 months. Create a free account to see the whole history
Results
Next results
03 Feb 2027
in 82 days · 11:00 · estimate 2.24
Last results
2.46 vs 2.26 estimated
27 Oct 2026 · Beat +8.6%
Beat the estimate
9 of 12
3 missed · 0 in line · 2 beats in a row
Average surprise
+4.5%
reported against the estimate, last 12 quarters
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 03 Feb 2027 11:00 | 2.24 | — | — | Upcoming |
| 27 Oct 2026 06:00 | 2.26 | 2.46 | +8.6% | Beat |
| 20 Jul 2026 20:00 | 2.14 | 2.41 | +12.7% | Beat |
| 27 Apr 2026 22:00 | 2.08 | 1.99 | -4.5% | Miss |
| 04 Feb 2026 01:00 | 2.07 | 2.03 | -1.7% | Miss |
| 28 Oct 2025 02:00 | 1.87 | 2.04 | +9.0% | Beat |
| 17 Jul 2025 01:00 | 2.37 | 2.42 | +2.0% | Beat |
| 29 Apr 2025 01:00 | 2.15 | 2.28 | +6.3% | Beat |
| 30 Jan 2025 20:00 | 1.82 | 1.98 | +8.7% | Beat |
| 28 Oct 2024 22:00 | 1.94 | 2.06 | +5.9% | Beat |
| 17 Jul 2024 22:00 | 1.87 | 1.97 | +5.5% | Beat |
| 23 Apr 2024 01:00 | 1.68 | 1.80 | +7.0% | Beat |
| 31 Jan 2024 01:00 | 1.61 | 1.53 | -5.3% | Miss |
| 23 Oct 2023 22:00 | 1.68 | 1.74 | +3.3% | Beat |
| 17 Jul 2023 21:00 | 1.70 | 1.83 | +7.4% | Beat |
| 25 Apr 2023 01:00 | 1.54 | 1.71 | +11.3% | Beat |
| 31 Jan 2023 20:00 | 1.41 | 1.52 | +7.4% | Beat |
| 25 Oct 2022 01:00 | 1.54 | 1.58 | +2.3% | Beat |
| 19 Jul 2022 01:00 | 1.49 | 1.56 | +4.5% | Beat |
| 26 Apr 2022 01:00 | 1.45 | 1.46 | +0.6% | In line |
| 02 Feb 2022 01:00 | 1.42 | 1.40 | -1.6% | Miss |
| 26 Oct 2021 01:00 | 1.64 | 1.71 | +4.2% | Beat |
| 21 Jul 2021 01:00 | 1.55 | 1.66 | +7.3% | Beat |
| 27 Apr 2021 01:00 | 1.54 | 1.52 | -1.1% | Miss |
| 25 Jan 2021 20:00 | 1.36 | 1.34 | -1.6% | Miss |
| 27 Oct 2020 02:00 | 1.46 | 1.52 | +4.4% | Beat |
| 21 Jul 2020 01:00 | 1.31 | 1.36 | +3.7% | Beat |
| 28 Apr 2020 02:00 | 1.38 | 1.56 | +12.9% | Beat |
| 28 Jan 2020 20:00 | 1.29 | 1.32 | +1.9% | Beat |
| 22 Oct 2019 01:00 | 1.33 | 1.41 | +6.4% | Beat |
| 18 Jul 2019 01:00 | 1.21 | 1.34 | +10.9% | Beat |
| 24 Apr 2019 01:00 | 1.14 | 1.21 | +6.2% | Beat |
| 30 Jan 2019 01:00 | 1.27 | 1.25 | -1.9% | Miss |
| 18 Oct 2018 01:00 | 1.29 | 1.32 | +2.6% | Beat |
| 18 Jul 2018 01:00 | 1.26 | 1.29 | +2.4% | Beat |
| 19 Apr 2018 01:00 | 1.26 | 1.28 | +1.6% | Beat |
| 24 Jan 2018 01:00 | 1.17 | 1.21 | +3.4% | Beat |
| 24 Oct 2017 01:00 | 1.25 | 1.29 | +3.4% | Beat |
| 18 Jul 2017 01:00 | 1.19 | 1.22 | +2.9% | Beat |
| 25 Apr 2017 01:00 | 1.12 | 1.13 | +1.2% | Beat |
| 25 Jan 2017 01:00 | 1.12 | 1.12 | -0.4% | In line |
| 25 Oct 2016 01:00 | 1.17 | 1.23 | +4.9% | Beat |
| 19 Jul 2016 01:00 | 1.19 | 1.23 | +3.4% | Beat |
| 21 Apr 2016 02:00 | 1.12 | 1.17 | +4.6% | Beat |
| 27 Jan 2016 01:00 | 1.21 | 1.12 | -7.4% | Miss |
| 27 Oct 2015 02:00 | 1.28 | 1.27 | -0.5% | In line |
| 21 Jul 2015 01:00 | 1.31 | 1.25 | -4.9% | Miss |
| 23 Apr 2015 01:00 | 1.19 | 1.29 | +8.7% | Beat |
| 27 Jan 2015 01:00 | 1.16 | 1.21 | +4.6% | Beat |
| 28 Oct 2014 03:00 | 1.31 | 1.37 | +4.3% | Beat |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 56.7B | +9.6% | 14B | 24.7% | 7.15 | +21.8% | 15.2B |
| 2024 | 51.7B | +10.8% | 11.9B | 23.1% | 5.87 | -17.3% | 13.8B |
| 2023 | 46.7B | +7.4% | 14.9B | 31.8% | 7.10 | +124.0% | 11.7B |
| 2022 | 43.5B | — | 7B | 16.0% | 3.17 | — | 12B |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| 13 Nov 2026 | 134.48 | 134.76 | 133.70 | 134.16 | -0.04% | 1,314,795 | |
| 12 Nov 2026 | 134.28 | 135.08 | 133.40 | 134.22 | +1.11% | 2,714,722 | |
| 11 Nov 2026 | 134.18 | 134.72 | 132.48 | 132.74 | -1.29% | 3,528,282 | |
| 10 Nov 2026 | 133.50 | 134.84 | 133.18 | 134.48 | +0.76% | 2,544,288 | |
| 09 Nov 2026 | 132.70 | 134.62 | 132.70 | 133.46 | +0.29% | 2,175,758 | |
| 06 Nov 2026 | 132.48 | 133.24 | 130.10 | 133.08 | -0.78% | 4,011,966 | |
| 05 Nov 2026 | 135.00 | 135.22 | 133.18 | 134.12 | -0.10% | 5,037,076 | |
| 04 Nov 2026 | 131.36 | 134.26 | 130.70 | 134.26 | +2.10% | 3,843,495 | |
| 03 Nov 2026 | 133.00 | 133.12 | 131.22 | 131.50 | -0.02% | 2,849,340 | |
| 02 Nov 2026 | 131.10 | 132.40 | 130.84 | 131.52 | -1.69% | 3,325,268 | |
| 1,256 older periods: create a free account to see the whole history | |||||||
Prices in CHF, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- Are You Looking for a Top Momentum Pick? Why Novartis (NVS) is a Great Choice (opens in a new tab) Zacks · 12 Nov 2026 16:00
- Amgen, In A Buy Zone, Unveils Highly Anticipated Novartis-Rivaling Sjogren's Data (opens in a new tab) Investor's Business Daily · 11 Nov 2026 21:02
- Is Novartis (SWX:NOVN) A Bargain Or Fully Priced Now? (opens in a new tab) Simply Wall St. · 11 Nov 2026 20:12
- Novartis (SWX:NOVN) Halts Pelacarsen After Trial Miss As Ianalumab Data Impresses (opens in a new tab) Simply Wall St. · 11 Nov 2026 14:15
- How IBD Stock Of The Day TG Therapeutics Is Catching Up To Roche, Novartis (opens in a new tab) Investor's Business Daily · 10 Nov 2026 22:12
- Zacks Industry Outlook Highlights Eli Lilly, Novartis and Bayer (opens in a new tab) Zacks · 10 Nov 2026 05:50
- Market Chatter: Novartis to Discontinue Development for Cardiovascular Disease Drug (opens in a new tab) MT Newswires · 09 Nov 2026 09:45
- Novartis shelves potential blockbuster pelacarsen as landmark study fails (opens in a new tab) Investing.com · 07 Nov 2026 15:46
- Update: Market Chatter: Novartis Reports Two Confirmed Tumor Cases Linked to Neuromuscular Gene Therapy (opens in a new tab) MT Newswires · 06 Nov 2026 10:48
- Novartis: 3 Key Takeaways for Long-Term Investors (opens in a new tab) Motley Fool · 04 Nov 2026 01:47
- Deutsche Bank turns bearish on Novartis as shares recover failed trial losses (opens in a new tab) Investing.com · 02 Nov 2026 10:16
- Novartis (SWX:NOVN) Reports Longer Survival In Advanced Kidney Cancer Trial (opens in a new tab) Simply Wall St. · 02 Nov 2026 01:07
- All You Need to Know About Novartis (NVS) Rating Upgrade to Buy (opens in a new tab) Zacks · 30 Oct 2026 15:00
- Earnings roundup: Lilly’s unwavering momentum, Novartis’ rebound and GSK’s waiting game (opens in a new tab) BioPharma Dive · 30 Oct 2026 11:50
- Lilly shuffles business structure; Novartis writes off part of Avidity deal (opens in a new tab) BioPharma Dive · 28 Oct 2026 13:27
Headlines link to the original articles of the publishers shown; Kyvero does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 134.22 CHF
- Market cap
- 253.6B
- Dividend yield
- 2.76%
- 5-year average yield
- 3.51%
- Payout ratio
- 87%
- Last dividend
- 3.7000 CHF · 10 Mar 2026
- Exchange
- Swiss
- Country
- Switzerland
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Currency
- CHF
Dividends
| Ex-dividend date | Per share |
|---|---|
| 10 Mar 2026 | 3.7000 CHF |
| 11 Mar 2025 | 3.5000 CHF |
| 07 Mar 2024 | 3.3000 CHF |
| 09 Mar 2023 | 3.2000 CHF |
| 8 older dividends: create a free account to see them | |
Why this score
| Part of the score | Points | Why |
|---|---|---|
| Yield Dividends per year as a share of today's price. Very high yields count for less: they often signal trouble. | 11.5 / 25 |
|
| Dividend safety Can the company keep paying? The dividend against free cash flow and earnings, plus debt and interest cover. | 19.4 / 25 |
|
| Dividend growth How many years in a row the dividend has risen, and how fast. | 14.2 / 15 |
|
| Quality Return on equity, net margin and how stable the margins are. | 10.4 / 15 |
|
| Valuation Free cash flow yield and the P/E against its sector. | 6.8 / 10 |
|
| Analysts How far the analysts' average target is from today's price. | 0.9 / 5 |
|
Income profile: it pays a dividend, so it is scored mainly on the dividend and how safe it is. Based on 95% of the figures (grade A).
Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio. How the score works
Figures
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| P/E (trailing) | 31.83× | Weak | 30.56× |
| P/E (forward) | 16.05× | Fair | 14.16× |
| Price / book | 8.17× | Weak | 3.5× |
| Price / sales | 4.37× | Fair | 3.33× |
| EV / EBITDA | 12.07× | Fair | 11.19× |
| Free cash flow yield | 4.5% | Fair | 2.1% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Gross margin | 75.2% | Good | 54.9% |
| Operating margin | 34% | Good | 5.8% |
| Net margin | 17.5% | Good | 1.2% |
| Return on equity | 24.3% | Good | 4.4% |
| Return on assets | 10.9% | Good | 2.7% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Revenue growth / year | 9.3% | Good | 10.1% |
| EPS growth / year | 31.1% | Good | 10.2% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Debt / equity | 1.29× | Fair | 0.4× |
| Net debt / EBITDA | 1.64× | Fair | 1.46× |
| Interest cover | 15.42× | Good | 2.17× |
| Current ratio | 0.88× | Weak | 2.64× |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Payout of earnings | 87.1% | Weak | 0% |
| Payout of free cash flow | 69.4% | Fair | 28.7% |
| Payout of free cash flow (3 years) | 55.7% | Fair | — |
| Dividend growth / year | 7.2% | Good | 6.5% |
| Years of rising dividends | 28 | Good | 1.5 |
The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.
Similar shares
Follow NOVN and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.